

## **Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in HHT**

C L Shovlin, J E Jackson, K B Bamford, I H Jenkins, A R Benjamin, H Ramadan, E Kulinskaya

### **LEGENDS TO ONLINE SUPPLEMENTARY FIGURES:**

#### **Figure S1: Effect of PAVM severity:**

A) Brain abscess and B) ischaemic stroke rates stratified by i) oxygen saturation standing SaO<sub>2</sub> and ii) size of largest PAVM feeding artery, severity increasing left-to-right: i) interquartile ranges:  $Q_1:59-88$ ;  $Q_2:88-93$ ;  $Q_3:93-96$ ;  $Q_4:96-100\%$ , ii)  $Q_1:0-3$ ;  $Q_2:3-5$ ;  $Q_3:5-6.5$ ;  $Q_4:6.5-12$ mm. Error bars: standard error of the mean.

#### **Figure S2: Anderson Gill proportional hazards models**

(A) Proportional survival until first ischaemic stroke: overall  $r^2 = 0.051$ , Wald test  $p=4.7\times 10^{-5}$ , Robust score  $p=2.00\times 10^{-2}$  (**for comparison, also presented in the text**).  
(B) Proportional survival until first brain abscess: overall  $r^2 = 0.017$ , Wald test  $p=6.3\times 10^{-3}$ , Robust score  $p=9.50\times 10^{-3}$ .

#### **Figure S3: Presentation pattern analyses**

A) Pretreatment SaO<sub>2</sub>; B) Age at PAVM diagnosis; C) Interval between PAVM diagnosis and treatment (**for comparison, also presented in the text**). RS: PAVM-related respiratory symptoms (dyspnoea and haemoptysis); Ix: incidental investigations; CNS: post stroke/abscess, HHT: via HHT screening programme.  $P$  values (ANOVA, Bonferroni post test corrections): \*\*\* $p<0.001$ ; \*\*:  $p<0.01$ ; \*:  $p<0.05$ ; ns:  $p>0.05$ .

## SUPPLEMENTARY TABLES

**Table S1 : Univariate associations of non-PAVM variables with brain abscess**

	N with/ without abscess	Event	Event-free group	P value*
<b>Non-PAVM variables</b>				
Gender, No. (%), % female	28/191	11 (39.3)	130 (67.7)	0.0054*
Hb, median (Q1, Q3), g/dl	27/186	15.1 (13.0, 16.4)	14.5 (12.8, 15.8)	0.35
Iron use, No. (%), %	28/175	12 (42.9)	61 (34.9)	0.41
Hormones, No. (%), %	22/180	2 (9.1)	37 (20.6)	0.26
Tranexamic acid, No. (%), %	26/187	1 (3.9)	7 (3.7)	0.99
Migraine, No. (%), %	28/189	8 (28.6)	82 (43.4)	0.16
Smoker§, No. (%), %	28/189	13 (46.4)	88 (46.6)	0.99
Hypertension, No. (%), %	28/189	3 (10.7)	33 (17.5)	0.59
Hypercholesterolaemia, No. (%), %	28/191	0 (0)	4 (2.1)	0.09
Diabetes, No. (%), %	28/188	0 (0)	7 (3.7)	0.99
Cardiac disease, No. (%), %	28/191	3 (10.7)	6 (3.2)	0.11
Atrial fibrillation, No. (%), %	27/188	1 (3.7)	6 (3.2)	0.99
FVIII:Ag, median (Q1, Q3), iu/l	17/90	1.85 (1.6, 3.0)	1.80 (1.52, 2.22)	0.44
PAP mean, median (Q1, Q3), mmHg	20/130	12.5 (10, 17)	13 (10.5, 16.0)	0.81
DVT/PE, No. (%), %	27/152	6 (22.2)	10 (6.8)	0.0186*

Legend: N = number of cases with/without abscess for which variable was measured. † more common in non-HHT patients (p<0.0001, Fisher's exact test 2 sided p value) . §f.a.d. feeding artery diameter.

**Table S2: Anderson Gill models for brain abscess**

	N	df	R <sup>2</sup>	Wald test P value	Robust score P value	Hazard ratio for variable (95% CI)	P value for variable in model
<b>Model 1 (pre emb)</b>	217	2	0.047	1.2 x10 <sup>-3</sup>	1.76x10 <sup>-2</sup>		
Gender (male)						3.61 (1.58, 8.25)	2.4x10 <sup>-3</sup>
DVT						3.35 (1.32, 8.50)	0.011
<b>Model 2 (pre+post emb)</b>	392	1	0.017	6.3x10 <sup>-3</sup>	9.50x10 <sup>-3</sup>		
Gender (male)						3.49 (1.43, 8.33)	6.3x10 <sup>-3</sup>
<b>Model 3 ( pre emb)</b>	316	3	0.03	0.015	0.029		
Gender (male)						4.55 (1.64, 12.5)	3.63x10 <sup>-3</sup>

SaO <sub>2</sub> , %					0.95 (0.89, 1.00)	0.058
Largest PAVM f.a.d.					0.98 (0.82, 1.17)	0.79

Models 1 and 2: Best model for brain abscess in untreated patients, and all patients pre and post embolisation (for comparison, also **presented in the text**). Model 3 is presented in view of the clinical importance of the PAVM variable findings. N, number of datapoints, df degrees of freedom.

**Table S3 Bacteriological cultures and potential precipitating events in patients with brain abscesses**

	Cases	Positive microbiology
<b>Treatment/condition</b>		
Scale and polish	3	<i>Streptococcus milleri</i> (2 cases)
Dental plates	1	<i>Bacteroides, Propionibacterium, Actinomyces meyeri</i>
Dental work & fillings	3	<i>Porphyromona, Gemella, Peptostreptococcus</i> (1 case)
Dental abscess	1	G+ve cocci, G+ve rods
Extraction	2	nil
Dental checks	1	nil
Poor dentition	2	G+ve rods
Oral radiotherapy	1	nil
Nasal cauterity	1	nil
Venous access	1	<i>MRSA, enterococcus</i>
Otitis media	1	nil

**Legend:** There were no data on interventional events in the 8-10 weeks prior to brain abscess in the other patients, four of whom had *Streptococcus milleri*, *Actinomyces israelii* or *bacteroides spp.* cultured from their abscess.

**Table S4: Univariate analyses of ischaemic stroke**

	N with/ without stroke	Event	Event-free group	P value*
<b>PAVM-associated variables</b>				
RS presentation, No. (%), %	30/186	8 (26.7)	39 (21)	0.48
SaO <sub>2</sub> , median (Q <sub>1</sub> , Q <sub>3</sub> ), %	25/157	93 (85, 96)	94(88.5, 96)	0.3
R-L, median (Q <sub>1</sub> , Q <sub>3</sub> ), %	24/105	11.0 (7.1, 19.5)	8.8 (4.7, 20.0)	0.32
Single PAVMs†, No. (%), %	29/181	7 (24.1)	44 (24.3)	0.99
Largest f.a.d. ‡, median (Q <sub>1</sub> , Q <sub>3</sub> ), mm	28/158	5.5 (4.0, 7.5)	5 (3.0, 6.0)	0.087
Small (f.a.d.≤3mm), No. (%), %	29/187	24 (82.8)	137 (73.3)	0.36
<b>Non PAVM-associated variables</b>				
Gender, No. (%), % female	30/189	22 (73.3)	119 (63.0)	0.36
Hb, median (Q <sub>1</sub> , Q <sub>3</sub> ), g/dl	30/183	14.2 (12.6, 16.1)	14.6 (12.9, 15.8)	0.67
Iron use, No. (%), %	29/172	15 (51.7)	57 (33.1)	0.063
Hormones, No. (%), %	28/172	7 (25)	30 (17.4)	0.43

Tranexamic acid, No. (%), %	29/182	0 (0)	8 (4.4)	0.6
Migraine, No. (%), %	30/185	9 (30)	80 (43.2)	0.23
Smoker§, No. (%), %	30/185	14 (46.7)	86 (46.5)	0.99
Hypertension, No. (%), %	30/185	8 (26.7)	28 (15.1)	0.12
Atrial fibrillation, No. (%), %	30/183	2 (6.7)	5 (2.7)	0.25
Hypercholesterolaemia, No. (%), %	30/187	2 (6.7)	2 (1.1)	0.09
Diabetes, No. (%), %	30/184	1 (3.3)	6 (3.3)	0.99
Cardiac disease, No. (%), %	30/187	3 (10)	6 (3.3)	0.11
FVIII:Ag, median ( $Q_1$ , $Q_3$ ), iu/l	15/90	2.01 (1.74, 2.76)	1.79 (1.54, 2.22)	0.12
PAP mean, median ( $Q_1$ , $Q_3$ ), mmHg	24/126	12 (10, 14.5)	13.0 (10.5, 16.0)	0.49
DVT/PE, No. (%), %	28/149	3 (10.7)	13 (8.8)	0.86

**Legend:** N = number of cases with/without ischaemic stroke for which variable was measured \* significant values at false discovery rate FDR=0.05 level <sup>37</sup>, § current or former smoker

**Table S5: Anderson Gill models for ischaemic stroke**

	N	df	R <sup>2</sup>	Wald test P value	Robust score P value	Hazard ratio for variable (95% confidence intervals)	P value for variable in model
<b>Model 4</b> (pre emb)	178	1	0.036	6.1x10 <sup>-4</sup>	3.20x10 <sup>-3</sup>		
PAP mean, mmHg						0.89 (0.83, 0.95)	6.2x10 <sup>-4</sup>
<b>Model 5</b> (pre +post emb)	250	4	0.051	4.7x10 <sup>-5</sup>	2.00x10 <sup>-2</sup>		
PAP mean, mmHg						0.85 (0.79, 0.92)	5.0x10 <sup>-5</sup>
Hb, g/dl						0.95 (0.72, 1.27)	0.75
Embolisation						5751.6 (2.5,1.3x10 <sup>7</sup> )	0.028
Hb, g/dl x Embolisation						1.84 (1.1, 3.07)	0.021
<b>Model 6</b> (pre emb)	347	2	0.001	0.75	0.75		
SaO <sub>2</sub> , %						0.95 (0.89, 1.00)	0.058
Largest PAVM f.a.d.						0.98 (0.82, 1.17)	0.79

Models 4 and 5: Best models for ischaemic stroke in untreated, and all patients pre and post embolisation (for comparison, also **presented in the text**). Model 6 is presented in view of the clinical importance of the PAVM variable findings. N, number of datapoints, df degrees of freedom.